Expired activity
Please go to the PowerPak homepage and select a course.

Non-Small Cell Lung Cancer: The Emerging Use of Immune Checkpoint Inhibitors in the Neoadjuvant Setting (Live Webinar)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.

Registration & Dates for Activities

Tuesday, May 17, 2022
3:00-4:00 PM ET
Wednesday, May 25, 2022
3:00-4:00 PM ET


Josiah D. Land, PharmD, BCOP
Clinical Pharmacist Specialist
Thoracic Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-22-035-L01-P
Credits: 1.0 hour (0.10 ceu)
Estimated time to complete activity: 60 minutes

Location: From the convenience of your home or business; accessible via both PC and MAC
Fee Information:
There is no fee for this educational activity.
Type of Activity:
Media: Internet


Oncology, managed care and specialty pharmacists


Introduction (5 minutes)
Presentation (45 minutes)
Conclusions & Question & Answer Session (10 minutes)


Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live event; and 3) complete the posttest and evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.or.


The goal of this activity is to provide oncology, managed care, and specialty pharmacists with enhanced knowledge on immune checkpoint inhibitor (ICI) use for resectable NSCLC in the neoadjuvant setting, including rationale for use, data from pivotal clinical trials, treatment-related toxicities, potential predictive biomarkers and surrogate endpoints. This will ensure that pharmacists are prepared to employ ICIs upon approval in this setting to improve patient outcomes and quality of life.


Upon completion of this activity, the participant should be better able to:

  • Identify potential predictive biomarkers and surrogate endpoints of neoadjuvant immunotherapy for NSCLC
  • Discuss emerging clinical trial data and the rationale for using neoadjuvant immune checkpoint inhibitors for treatment of early-stage NSCLC
  • Formulate approaches for mitigation of common toxicities associated with neoadjuvant immunotherapy for NSCLC


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5